Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.
decision curve analysis
efficacy
liver decompensation
safety
total bilirubin
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
24
05
2022
received:
17
02
2022
accepted:
23
06
2022
pubmed:
7
8
2022
medline:
28
9
2022
entrez:
6
8
2022
Statut:
ppublish
Résumé
Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with "advanced cirrhosis" because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic serious adverse events (SAEs) and non-response in cirrhotic patients undergoing OCA therapy. Safety and efficacy of treatment were evaluated in a cohort of consecutive PBC cirrhotic patients started with OCA. OCA response was evaluated according to the Poise criteria. Risk factors for hepatic SAEs and non-response were reported as risk ratios (RR) with 95% confidence intervals (CIs). One hundred PBC cirrhotics were included, 97 Child-Pugh class A and 3 class B. Thirty-one had oesophageal varices and 5 had a history of ascites. Thirty-three per cent and 32% of patients achieved a biochemical response at 6 and 12 months respectively. Male sex (adjusted-RR 1.75, 95%CI 1.42-2.12), INR (1.37, 1.00-1.87), Child-Pugh score (1.79, 1.28-2.50), MELD (1.17, 1.04-1.30) and bilirubin (1.83, 1.11-3.01) were independently associated with non-response to OCA. Twenty-two patients discontinued OCA within 12 months: 10 for pruritus, 9 for hepatic SAEs (5 for jaundice and/or ascitic decompensation; 4 for upper digestive bleeding). INR (adjusted-RR 1.91, 95%CI 1.10-3.36), lower albumin levels (0.18, 0.06-0.51), Child-Pugh score (2.43, 1.50-4.04), history of ascites (3.5, 1.85-6.5) and bilirubin (1.30, 1.05-1.56), were associated with hepatic SAEs. A total bilirubin≥1.4 mg/dl at baseline was the most accurate biochemical predictor of hepatic SAEs under OCA. An accurate baseline assessment is crucial to select cirrhotic patients who can benefit from OCA. Although OCA is effective in one third of cirrhotics, bilirubin level ≥1.4 mg/dl should discourage from its use.
Sections du résumé
BACKGROUND & AIMS
Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with "advanced cirrhosis" because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic serious adverse events (SAEs) and non-response in cirrhotic patients undergoing OCA therapy.
METHODS
Safety and efficacy of treatment were evaluated in a cohort of consecutive PBC cirrhotic patients started with OCA. OCA response was evaluated according to the Poise criteria. Risk factors for hepatic SAEs and non-response were reported as risk ratios (RR) with 95% confidence intervals (CIs).
RESULTS
One hundred PBC cirrhotics were included, 97 Child-Pugh class A and 3 class B. Thirty-one had oesophageal varices and 5 had a history of ascites. Thirty-three per cent and 32% of patients achieved a biochemical response at 6 and 12 months respectively. Male sex (adjusted-RR 1.75, 95%CI 1.42-2.12), INR (1.37, 1.00-1.87), Child-Pugh score (1.79, 1.28-2.50), MELD (1.17, 1.04-1.30) and bilirubin (1.83, 1.11-3.01) were independently associated with non-response to OCA. Twenty-two patients discontinued OCA within 12 months: 10 for pruritus, 9 for hepatic SAEs (5 for jaundice and/or ascitic decompensation; 4 for upper digestive bleeding). INR (adjusted-RR 1.91, 95%CI 1.10-3.36), lower albumin levels (0.18, 0.06-0.51), Child-Pugh score (2.43, 1.50-4.04), history of ascites (3.5, 1.85-6.5) and bilirubin (1.30, 1.05-1.56), were associated with hepatic SAEs. A total bilirubin≥1.4 mg/dl at baseline was the most accurate biochemical predictor of hepatic SAEs under OCA.
CONCLUSIONS
An accurate baseline assessment is crucial to select cirrhotic patients who can benefit from OCA. Although OCA is effective in one third of cirrhotics, bilirubin level ≥1.4 mg/dl should discourage from its use.
Identifiants
pubmed: 35932095
doi: 10.1111/liv.15386
pmc: PMC9804305
doi:
Substances chimiques
Albumins
0
obeticholic acid
0462Z4S4OZ
Chenodeoxycholic Acid
0GEI24LG0J
Bilirubin
RFM9X3LJ49
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2453-2465Investigateurs
Valentina Feletti
(V)
Alessandro Mussetto
(A)
Rosanna Venere
(R)
Giulia Bernaccioni
(G)
Marie Graciella Pigozzi
(M)
Stefano Fagiuoli
(S)
Natalia Terreni
(N)
Pietro Pozzoni
(P)
Leonardo Baiocchi
(L)
Giuseppe Grassi
(G)
Maria Vinci
(M)
Valentina Bellia
(V)
Roberto Boldizzoni
(R)
Silvia Casella
(S)
Barbara Omazzi
(B)
Guido Poggi
(G)
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
JHEP Rep. 2021 Jan 27;3(2):100248
pubmed: 33681748
Hepatology. 2022 Apr;75(4):1012-1013
pubmed: 34431119
Lancet Gastroenterol Hepatol. 2018 Sep;3(9):626-634
pubmed: 30017646
J Hepatol. 2017 Jul;67(1):145-172
pubmed: 28427765
Sci Rep. 2018 Nov 8;8(1):16529
pubmed: 30409980
Hepatology. 2020 Apr;71(4):1511-1514
pubmed: 31680292
Lancet Gastroenterol Hepatol. 2019 Jun;4(6):445-453
pubmed: 30922873
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
Aliment Pharmacol Ther. 2021 Feb;53(4):519-530
pubmed: 33314220
Scand J Gastroenterol. 2019 Oct;54(10):1274-1282
pubmed: 31564176
Hepatology. 2014 Jun;59(6):2286-98
pubmed: 24259407
Ultraschall Med. 2012 Feb;33(1):8-32; quiz 30-1
pubmed: 22322479
Liver Int. 2022 Nov;42(11):2453-2465
pubmed: 35932095
N Engl J Med. 2016 Aug 18;375(7):631-43
pubmed: 27532829
Am J Gastroenterol. 2020 Jul;115(7):1066-1074
pubmed: 32618657
Hepatol Commun. 2021 May 06;5(8):1426-1436
pubmed: 34430786
J Hepatol. 1997 Dec;27(6):979-85
pubmed: 9453422
N Engl J Med. 2018 Jun 07;378(23):2171-2181
pubmed: 29874528
Hepatol Commun. 2020 Jul 06;4(9):1332-1345
pubmed: 32923836
Radiology. 2003 Apr;227(1):89-94
pubmed: 12601199
Gastroenterology. 2013 Mar;144(3):560-569.e7; quiz e13-4
pubmed: 23246637
J Hepatol. 2021 Jan;74(1):58-65
pubmed: 32717289